FierceBiotech

Axonics nabs Canadian nod for 20-year incontinence implant requiring fewer recharges

Hot on the heels of the U.S. launch of its recharge-free neurostimulation implant to treat incontinence, Axonics is bringing yet another of its sacral neuromodulation (SNM) devices to our neighbors to ...
Business Wire

Axonics Acquires Technology to Facilitate Easier and Faster Placement of Implantable Leads for Sacral Neuromodulation

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel ...
FierceBiotech

Axonics clears FDA to bring latest version of 20-year neurostim implant to US

A month after landing Canadian approval for its updated neuromodulation implant to treat incontinence, Axonics is bringing the fourth-generation R20 device across the border. The FDA has approved the ...
The Greeley Tribune

‘Helping women live their best lives’: Implant restores Severance woman’s bladder control

A 41-year-old nurse from Severance shopping for a solution to her overactive bladder symptoms found a way to regain full control thanks to an innovative procedure. Sarah Avrech said goodbye to a life ...
Nasdaq

Leerink Partners Initiates Coverage of Axonics (AXNX) with Outperform Recommendation

As of October 5, 2023, the average one-year price target for Axonics is 77.91. The forecasts range from a low of 60.60 to a high of $99.75. The average price target represents an increase of 43.14% ...